Correction of Data Discrepancies in Table and Text

Overview

This report addresses corrections made to the original investigation on navepegritide in children with achondroplasia, specifically regarding participant data discrepancies, including the number of female participants and textual inaccuracies. The corrections were necessary to ensure accurate representation of the study's findings.

Background

Accurate data reporting in clinical trials is crucial for the integrity of research and subsequent clinical applications. Discrepancies in participant data can lead to misinterpretations of treatment efficacy and safety. The corrections made in this study highlight the importance of rigorous data validation in clinical research.

Data Highlights

Corrections were made to participant data, including the number of female participants in Table 1 and textual discrepancies.

Key Findings

• The number of female participants in the APPROACH trial was corrected in Table 1.
• Textual discrepancies regarding participant data were also amended, including specific inaccuracies in participant demographics.
• Previous corrections included the addition of CC-BY-NC-ND Open Access status.
• A rounding error in Figure 3 was corrected in a subsequent update.
• Accurate data reporting is essential for maintaining the credibility of clinical research findings.

Clinical Implications

Healthcare professionals should remain vigilant about data accuracy in clinical studies, as discrepancies can significantly impact treatment decisions and patient outcomes. Continuous monitoring and validation of data are essential to uphold the quality of clinical research.

Conclusion

The corrections made to the APPROACH trial underscore the necessity for meticulous data management in clinical research. Ensuring accuracy in reported findings and transparency in corrections is vital for the advancement of treatment protocols.

References

1. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial, JAMA Pediatrics, 2025 -- Original Investigation
2. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia, Nature Reviews Endocrinology, 2021 -- Consensus Guidelines
3. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia, Nature Reviews Endocrinology, 2024 -- Implementation Guidelines
4. Erratum: 3D Reconstruction from Microscopic Imaging for Computer-Assisted Eye Surgery
5. Erratum: Compliance with Multi-Target Stool DNA Testing for Colorectal Cancer Screening in the U.S.
6. Drug Safety — Correction: Assessment of Characteristics of Duplicate Adverse Event Reports in the FDA Adverse Event Reporting System
7. Blood Cancer Journal — Author Correction: Clonal hematopoiesis in patients with rheumatoid arthritis
8. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia | Nature Reviews Endocrinology
9. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia | Nature Reviews Endocrinology
10. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial | Trials | JAMA Pediatrics | JAMA Network